Reviews/COPD Pharmacotherapy/Single-inhaler triple therapy adherence
Triple Therapy · COPD-TT-03 · v2
The idea behind this claim is simple: if a patient takes one combined inhaler instead of juggling several, they should find it easier to keep up with treatment. The corpus offers one head-to-head study [2] that followed real patients and found that those on a single inhaler took their medication more consistently and stayed on treatment longer than those on multiple inhalers. Two other surveys [10] and [12] point the same way, linking single-inhaler use and fewer medications to better adherence. But the one randomised trial in the set [1] never actually measured adherence, and the single study that did compare the two approaches directly was not an experiment, so sicker patients landing in one group rather than the other could explain the difference. The panel found the direction of the evidence believable and consistent, but judged it too thin and too open to bias to treat as settled.
Only one study in the corpus directly compares single-inhaler triple therapy with multiple-inhaler triple therapy on adherence: the prospective observational cohort [2], which reports a higher proportion of patients with PDC >=0.8 (86.5% vs. 79.8%; p = 0.006) and greater treatment persistence (HR 1.676, 1.356-2.071) with the single inhaler. Cross-sectional data support the underlying mechanism, with single-inhaler use associated with good adherence and multiple-inhaler use carrying a lower odds of satisfaction (aOR 0.62, 0.39-0.99) in [10], and adherence negatively correlated with the number of medications (r = -0.147, p = 0.011) in [12]. The only randomised head-to-head [1] did not report an adherence endpoint and recorded numerically more critical inhalation-technique errors with the single inhaler (6% vs 3%). No randomised adherence comparison exists anywhere in this corpus. The contested point: The evidence divides on whether the adherence advantage in [2] is caused by the single inhaler or by the fact that its SITT group was sicker (higher CAT, lower FEV1, more prior exacerbations) with an apparently unadjusted comparison. The cross-sectional studies [10] and [12] are open to the reverse reading, that already-adherent patients are preferentially given single inhalers, rather than single inhalers producing adherence.
All 14 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from COPD Pharmacotherapy, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The claim's direct support is a single observational cohort [2] with clear channeling bias: the SITT group was sicker (higher CAT, lower FEV1, more prior exacerbations), and the PDC comparison appears unadjusted for severity, so the adherence gap may be confounded rather than caused by inhaler count.
The only randomised head-to-head [1] did not report adherence as an endpoint, and its adherence-adjacent proxy — critical inhalation-technique errors — was numerically worse with the single inhaler (6% vs 3%); no RCT-grade adherence evidence supports the claim.
Where it remains uncertain. The sole direct study [2] is observational with a sicker, apparently unadjusted single-inhaler group, and the only randomised head-to-head [1] did not measure adherence.
Aleatory
Adherence instruments carry inherent inter-patient variability and external-factor noise, as the hair-assay validation [11] shows a weak digital-inhaler correlation (r = .25, p = .087).
Epistemic
The corpus contains no RCT that measured adherence; the one randomised head-to-head [1] omitted the endpoint, so the strongest design is absent and could be collected.
Inferential
In [2] the SITT group was sicker and the PDC comparison appears unadjusted, so severity may drive both treatment choice and adherence rather than inhaler count.
The load-bearing papers from a corpus of 14, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Only direct SITT-vs-MITT adherence/persistence comparison in the corpus; positive and statistically significant, but observational.
“SITT patients had, compared to MITT patients, a higher proportion of adherence (proportion of days covered, PDC) ≥0.8 (86.5% vs. 79.8%; p = 0.006), higher treatment persistence [HR: 1.676 (1.356-2.071), p < 0.001]”
Panel auditInternal validity: medium · scope of inference: Chinese COPD patients, SITT vs MITT persistence, adherence and exacerbations over 12 months.Key limitations: observational, confounding by indication · baseline imbalance between groups · single country
Cross-sectional association linking single-inhaler use to good adherence; supportive of mechanism, not triple-specific or causal.
“Good adherence (Test of Adherence to Inhalers [10-item questionnaire] = 50) was observed in 32.9%, associated with adequate inhaler knowledge, absence of forgetfulness or fear, single-inhaler use, and higher satisfaction (all P < .001).”
Panel auditInternal validity: low · scope of inference: Inhaler satisfaction and adherence in a South Indian COPD clinic population.Key limitations: cross-sectional, association only · not triple-therapy specific · single centre
Inverse correlation between medication count and adherence supports the regimen-complexity rationale underlying the claim.
“negative correlations with the number of medications ( r = -0.147, p = 0.011)”
Panel auditInternal validity: low · scope of inference: Determinants of inhaler adherence in COPD patients in Turkey and Greece.Key limitations: correlational · number of medications is not inhaler count · no SITT vs MITT comparison
The abstract's endpoints are CAT responders, FEV1 and critical inhalation errors; adherence is never measured.
Panel auditInternal validity: medium · scope of inference: COPD patients in usual clinical care across five European countries, health-status and lung-function outcomes at 24 weeks.Key limitations: open-label · adherence not an endpoint · 24-week horizon
4 of 14 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Directionally consistent, mechanistically plausible support kept below Likely because the sole direct comparison is a single confounded observational cohort with no corroborating randomised adherence data.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No randomised adherence comparison. The claim's causal reading needs an experiment, yet the only RCT [1] omitted adherence and every adherence study is observational. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomised trial assigning COPD patients to single-inhaler versus multiple-inhaler triple therapy with adherence (PDC or persistence) as a pre-specified endpoint.
Open question: Does moving a COPD patient from multiple-inhaler to single-inhaler triple therapy causally improve adherence? Why it is still open: The only randomised head-to-head [1] did not measure adherence, and the sole direct comparison [2] is observational, so causation is untested.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19